Related Experiment Video

Updated: Mar 14, 2026

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
09:08

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

7.3K

Downregulation of Notch Signaling Pathway as an Effective Chemosensitizer for Cancer Treatment

M Majidinia1, E Alizadeh2, B Yousefi1

  • 1Department of Clinical Biochemistry and Laboratory Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.

Drug Research
|October 5, 2016
PubMed

Insights

Targeting the Notch signaling pathway can help overcome multidrug resistance (MDR) in cancer. This approach offers a novel strategy to improve tumor treatment by sensitizing cancer cells to chemotherapy and preventing recurrence.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Drug resistance remains a significant challenge in cancer therapy, leading to treatment failure and tumor recurrence.
  • Several signaling pathways contribute to the development of chemotherapy resistance.
  • The Notch signaling pathway plays a crucial role in regulating cell proliferation, apoptosis, cancer stem cell properties, tumor immunity, and multidrug resistance.

Purpose of the Study:

  • To review the evidence supporting the targeting of the Notch signaling pathway as a strategy to overcome multidrug resistance (MDR) in cancer.
  • To highlight the potential of Notch pathway inhibition as a novel and safer approach to enhance cancer treatment efficacy.

Main Methods:

  • Literature review of published studies on Notch signaling and multidrug resistance.
  • Analysis of evidence demonstrating the role of Notch in acquiring drug resistance.
  • Evaluation of studies investigating Notch pathway inhibitors for cancer therapy.

Main Results:

  • The Notch signaling pathway is implicated in various aspects of cancer biology, including the development of MDR.
  • Targeting the Notch pathway has shown potential in reverting drug resistance in preclinical models.
  • Inhibition of Notch signaling may re-sensitize tumor cells to chemotherapeutic agents.

Conclusions:

  • The Notch signaling pathway is a promising therapeutic target for overcoming MDR in cancer.
  • Targeting Notch signaling represents a novel and potentially safer strategy to improve outcomes in cancer treatment.
  • Further research into Notch pathway inhibitors is warranted to develop effective clinical applications.

More Related Videos

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

9.2K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.7K

Related Concept Videos

Notch Signaling Pathway03:14

Notch Signaling Pathway

The Notch signaling pathway is a major intracellular signaling pathway that is highly conserved over a broad spectrum of metazoan species. It stands unique from other intracellular signaling mechanisms in animals because notch protein itself acts as the receptor as well as the primary signaling molecule.
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
6.8K
Notch Signaling Pathway03:14

Notch Signaling Pathway

6.4K
Role Of Notch Signalling In Intestinal Stem Cell Renewal01:12

Role Of Notch Signalling In Intestinal Stem Cell Renewal

Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
2.6K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.9K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.7K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
715